NONALCOHOLIC STEATOHEPATITIS
Clinical trials for NONALCOHOLIC STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise against fatty liver and scarring
Disease control CompletedThis study tested a drug called saroglitazar magnesium in 189 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease with inflammation and scarring. The goal was to see if the drug could reduce liver inflammation and scarring without making the disease wor…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
New shot targets fatty liver disease in genetically At-Risk patients
Disease control CompletedThis study tested a new medicine called AZD2693 in 220 adults with a type of fatty liver disease (NASH) and liver scarring, who also carry a specific gene variant (PNPLA3 148M). The goal was to see if the drug could reverse the liver damage or stop it from getting worse over 52 w…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 01, 2026 16:00 UTC